INmune Bio Operating Expenses 2018-2025 | INMB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

INmune Bio operating expenses from 2018 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

INmune Bio operating expenses from 2018 to 2025. Operating expenses can be defined as the sum of all operating expenses for the given industry.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$248.1B
Amgen (AMGN)	$153.8B
Gilead Sciences (GILD)	$139.7B
Vertex Pharmaceuticals (VRTX)	$100.5B
Bristol Myers Squibb (BMY)	$95.4B
GSK (GSK)	$80.3B
CSL (CSLLY)	$66.8B
Regeneron Pharmaceuticals (REGN)	$61.4B
Alnylam Pharmaceuticals (ALNY)	$59.3B
Argenex SE (ARGX)	$43.1B
Insmed (INSM)	$28.5B
BioNTech SE (BNTX)	$24.5B
Royalty Pharma (RPRX)	$20.8B
Biogen (BIIB)	$19.4B
Genmab (GNMSF)	$16.4B
Incyte (INCY)	$16.3B
Genmab (GMAB)	$16.1B
Illumina (ILMN)	$15.2B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.3B
Exelixis (EXEL)	$10.2B
Moderna (MRNA)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$9.2B
Exact Sciences (EXAS)	$8.9B
Bio-Techne Corp (TECH)	$8.5B
Halozyme Therapeutics (HALO)	$8.5B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B